Published in Anticancer Agents Med Chem on February 01, 2014
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience (2014) 0.94
Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. EBioMedicine (2015) 0.86
Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production. EBioMedicine (2015) 0.82
The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. Oncotarget (2015) 0.81
MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncoimmunology (2015) 0.81
IFNα signaling through PKC-θ is essential for antitumor NK cell function. Oncoimmunology (2014) 0.78
Application of Glutamine-enriched nutrition therapy in childhood acute lymphoblastic leukemia. Nutr J (2016) 0.75
CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. PLoS One (2016) 0.75
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
On respiratory impairment in cancer cells. Science (1956) 14.07
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 11.71
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
Functions of natural killer cells. Nat Immunol (2008) 9.88
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09
Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem (1979) 6.53
Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci (2010) 6.30
LKB1-dependent signaling pathways. Annu Rev Biochem (2006) 5.91
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A (2010) 4.99
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A (2010) 4.18
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res (2004) 4.03
Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med (2010) 3.99
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature (2012) 3.85
SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab (2012) 3.69
The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res (2007) 3.55
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2012) 3.35
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res (2009) 3.15
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene (1998) 2.92
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell (2012) 2.82
Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell (2011) 2.80
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J (2007) 2.52
Metabolic checkpoints in activated T cells. Nat Immunol (2012) 2.47
Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol (2010) 2.31
The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res (2009) 2.29
Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 2.27
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia (2005) 2.15
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia (2008) 1.97
Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res (2009) 1.96
Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys (2010) 1.91
Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature (2012) 1.88
Viral mechanisms of immune evasion. Trends Microbiol (2000) 1.85
p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2009) 1.79
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008) 1.78
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 1.77
Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) (2011) 1.67
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One (2009) 1.58
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet (2005) 1.49
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma (2012) 1.47
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell (2011) 1.44
Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics (2008) 1.44
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood (2010) 1.38
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol (2006) 1.37
p53 in hematologic malignancies. Blood (1994) 1.37
PPAR control: it's SIRTainly as easy as PGC. J Endocrinol (2009) 1.33
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood (2009) 1.28
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia (2009) 1.26
MYC, microRNAs and glutamine addiction in cancers. Cell Cycle (2009) 1.26
The Role of p53 in Metabolic Regulation. Genes Cancer (2011) 1.25
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol (2007) 1.24
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol (2010) 1.17
Mammalian sirtuins and energy metabolism. Int J Biol Sci (2011) 1.17
DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood (2011) 1.16
Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci (Landmark Ed) (2009) 1.16
Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase. Int J Cancer (1978) 1.14
Rescue of mutant p53 transcription function by ellipticine. Oncogene (2003) 1.14
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res (2011) 1.13
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia (2011) 1.13
Distinctions and similarities of cell bioenergetics and the role of mitochondria in hypoxia, cancer, and embryonic development. Int J Biochem Cell Biol (2009) 1.11
ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol (2006) 1.06
Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci (2011) 1.06
LKB1 and AMPK: central regulators of lymphocyte metabolism and function. Immunol Rev (2012) 1.05
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle (2012) 1.03
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J Med Chem (2010) 1.03
The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol (2012) 1.03
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia (2011) 1.02
From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol (2012) 1.02
Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J Med Chem (2012) 0.98
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood (2011) 0.96
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem (2012) 0.96
The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther (2012) 0.95
Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol (2007) 0.92
Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol (2002) 0.91
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Ther Targets (2012) 0.91
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One (2009) 1.84
Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J Neurosci (2002) 1.54
Protein kinase C-theta (PKCtheta): it's all about location, location, location. Immunol Rev (2003) 1.28
SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol (2004) 1.24
Erk5 controls Slug expression and keratinocyte activation during wound healing. Mol Biol Cell (2008) 1.20
Activation of cyclin D1 expression by the ERK5 cascade. Oncogene (2003) 1.14
ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol (2006) 1.06
SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol (2008) 1.03
The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol (2012) 1.03
Positive feedback regulation of PLCgamma1/Ca(2+) signaling by PKCtheta in restimulated T cells via a Tec kinase-dependent pathway. Eur J Immunol (2004) 1.03
From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol (2012) 1.02
Protein kinase C-theta (PKC theta): a key enzyme in T cell life and death. J Biochem (2002) 0.99
Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF. Oncogene (2003) 0.98
Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. Mol Cell Biol (2002) 0.98
Guanine exchange-dependent and -independent effects of Vav1 on integrin-induced T cell spreading. J Immunol (2003) 0.96
ERK5 knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis. J Immunol (2009) 0.90
Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity. Front Immunol (2012) 0.90
Impaired anti-leukemic immune response in PKCtheta-deficient mice. Mol Immunol (2008) 0.89
Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J Immunol (2010) 0.89
P2 receptors in bone--modulation of osteoclast formation and activity via P2X7 activation. Crit Rev Eukaryot Gene Expr (2003) 0.87
TC10 controls human myofibril organization and is activated by the sarcomeric RhoGEF obscurin. J Cell Sci (2009) 0.87
Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol (2011) 0.86
Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival. Eur J Haematol (2014) 0.85
Dimer formation and conformational flexibility ensure cytoplasmic stability and nuclear accumulation of Elk-1. Nucleic Acids Res (2011) 0.82
Angiogenesis and acute myeloid leukemia. Hematology (2013) 0.81
The protooncogene Vav1 regulates murine leukemia virus-induced T-cell leukemogenesis. Oncoimmunology (2012) 0.77
[SUMO pins Elk-1 in the nucleus]. Med Sci (Paris) (2005) 0.75